Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 20

Results For "Rs-1"

270 News Found

Panacea Biotec sells its domestic formulations business to Mankind Pharma
News | February 02, 2022

Panacea Biotec sells its domestic formulations business to Mankind Pharma

The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year


Dr Reddy’s numbers in line; launches in FY23 likely drivers: ICICI Direct
News | January 31, 2022

Dr Reddy’s numbers in line; launches in FY23 likely drivers: ICICI Direct

ICICI Direct analysis of Dr Reddy’s Q3FY22 results


Cipla has strong traction in India and the US: ICICI Direct
News | January 31, 2022

Cipla has strong traction in India and the US: ICICI Direct

ICICI Direct’s analysis of Cipla’s Q3FY22 results


Foreign Direct Investment in pharma grows at rapid pace: Eco Survey
News | January 31, 2022

Foreign Direct Investment in pharma grows at rapid pace: Eco Survey

In the April-September 2021 period, the FDI inflows continued to be buoyant at Rs 4,413 crore, growing at the rate of 53 per cent over the same period in 2020-21


ARVs bottom out while CRAMS growth continues for Laurus Labs: ICICI Direct
News | January 29, 2022

ARVs bottom out while CRAMS growth continues for Laurus Labs: ICICI Direct

The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct


Covaxin and Covishield granted conditional market approval
News | January 27, 2022

Covaxin and Covishield granted conditional market approval

The vaccines are currently only authorised for emergency use in the country


Cipla’s Q3FY22 PAT at Rs 729 cr.
News | January 26, 2022

Cipla’s Q3FY22 PAT at Rs 729 cr.

Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.


JBCPL to acquire brands from Sanzyme for Rs 628 cr
News | January 26, 2022

JBCPL to acquire brands from Sanzyme for Rs 628 cr

Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise


Novo Nordisk India launches world’s first and only GLP-1 RA, oral semaglutide
Drug Approval | January 20, 2022

Novo Nordisk India launches world’s first and only GLP-1 RA, oral semaglutide

Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach


Normalised quarter with impending margin pressure: ICICI Direct
News | January 13, 2022

Normalised quarter with impending margin pressure: ICICI Direct

ICICI Direct gives a preview on the earnings narrative for Q3FY22